Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines

Molecular and Cellular Biochemistry

Volumn 350, Issue 1-2, 2011, Pages 59-70

  Bocca, Claudia ^a   Bozzo, Francesca ^a   Bassignana, Andrea ^a   Miglietta, Antonella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; Celecoxib; COX 2; ER; PI3K Akt

Indexed keywords

AROMATASE; CELECOXIB; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PYRAZOLES; SULFONAMIDES;

EID: 79953702230     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-010-0682-4     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E et al (2010) Cancer statistics. CA Cancer J Clin 60:277-300
2. Reeder JG, Vogel VG (2007) Breast cancer risk management. Clin Breast Cancer 7:833-840
3. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8:97-114 (Pubitemid 32641352)
4. Ristimäki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632-635 (Pubitemid 34126931)
5. Richards JA, Petrel TA, Brueggemeier RW (2002) Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 80:203-212 (Pubitemid 34233740)
6. Mazhar D, Ang R, Wazman J (2006) COX inhibitors and breast cancer. Br J Cancer 94:346-350 (Pubitemid 43237558)
7. Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 20:2433-2440 (Pubitemid 38669186)
8. Brueggemeier RW, Su B, Sugimoto Y et al (2007) Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol 106:16-23 (Pubitemid 47362646)
9. Díaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90:2563-2570 (Pubitemid 40686292)
10. Prosperi JR, Robertson FM (2006) Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 81:55-70 (Pubitemid 44403171)
11. Altundag K, Ibrahim NK (2006) Aromatase inhibitors in breast cancer: an overview. Oncologist 11:553-562 (Pubitemid 43967611)
12. Gill K, Kirma N, Tekmal RR (2001) Overexpression of aromatase in transgenic male mice in the induction of gynecomastia and other biochemical changes in mammary glands. J Steroid Biochem Mol Biol 77:13-18 (Pubitemid 32455349)
13. Hammes SR, Levin ER (2007) Extranuclear steroid receptors: nature and actions. Endocr Rev 28:726-741 (Pubitemid 350294293)
14. Wong CW, McNally C, Nickbarg E et al (2002) Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99:14783-14788 (Pubitemid 35334561)
15. Campbell RA, Bhat-Nakshatri P, Patel NM et al (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:9817-9824
16. Levin ER (2005) Integration of the extra-nuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951-1959
17. Reddy BS, Hirose Y, Lubet R et al (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60:293-297 (Pubitemid 30070754)
18. Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27-31
19. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL (2005) Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115:484-492 (Pubitemid 40663755)
20. Del Grosso E, Boschi D, Lazzarato L et al (2005) The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities. Chem Biodivers 2:886-900 (Pubitemid 41057407)
21. Bozzo F, Bassignana A, Lazzarato L et al (2009) Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth. Chem Biol Interact 182:183-190
22. Boschi D, Lazzarato L, Rolando B et al (2009) Nitrooxymethyl substituted analogues of celecoxib: synthesis and pharmacological characterization. Chem Biodivers 6:369-379
23. Chang F, Lee JT, Navolanic PM et al (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590-603 (Pubitemid 36395654)
24. Cannito S, Novo E, Compagnone A et al (2008) Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29:2267-2278
25. Ikeda K, Inoue S (2004) Estrogen receptors and their downstream targets in cancer. Arch Histol Cytol 64:67435-67442
26. Lu Q, Surks HK, Ebling H, Baur WE, Brown D, Pallas DC, Karas RH (2003) Regulation of estrogen receptor alpha-mediated transcription by a direct interaction with protein phosphatase 2A. J Biol Chem 278:4639-4645 (Pubitemid 36800962)
27. Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905-2919
28. Howe LR (2007) Inflammation and breast cancer. Cyclooxygenase/ prostaglandin signaling and breast cancer. Breast Cancer Res 9:210-211
29. Di GH, Lu JS, Song CG et al (2005) Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas. Exp Clin Cancer Res 24:601-607 (Pubitemid 43140740)
30. Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229-239 (Pubitemid 39440251)
31. Juuti A, Louhimo J, Nordling S et al (2006) Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 59:382-386
32. Liu CH, Chang SH, Narko K et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569
33. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000) Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7:1377-1381
34. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649-18657
35. Perez-Tenorio G, Stal O (2002) Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545 (Pubitemid 34185089)
36. Tokunaga E, Kimura Y, Oki E et al (2006) Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118:284-289 (Pubitemid 41779066)
37. Mawson A, Lai A, Carroll JS et al (2005) Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 229:161-173 (Pubitemid 40018094)
38. Kato S, Endoh H, Masuhiro Y et al (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
39. Martin MB, Franke TF, Stoica TF et al (2000) A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141:4503-4511 (Pubitemid 32055127)
40. Ranatunge RR, Augustyniak M, Bandarage UK et al (2004) Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. J Med Chem 47:2180-2193 (Pubitemid 38478842)
41. Chegaev K, Lazzarato L, Tosco P et al (2007) NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J Med Chem 50:1449-1457 (Pubitemid 46564368)